blank
blank

ERDERA Strategic Research and Innovation Agenda

1:1
The SRIA sets ERDERA’s objectives and performance indicators to guide rare disease research and innovation across Europe.

This Strategic Research and Innovation Agenda (SRIA) describes the SRIA development process and sets out the ambition, vision and mission of the European Rare Diseases Research Alliance (ERDERA). It defines ERDERA’s general, specific and operational objectives, and includes performance indicators for monitoring and evaluation.

Acces this publication
blank

publication

cover for the ERDERA Strategic Research and Innovation Agenda (2024)

Source

ERDERA

You might also be interested in

ECRD 2026

ECRD 2026 in Prague strengthens the push for a coordinated EU Action Plan on rare diseases

On 3–4 June, EURORDIS–Rare Diseases Europe and Orphanet convened the rare disease community at ECRD 2026 in Prague around a shared call for coordinated European action, including the forthcoming European Blueprint for Rare Diseases.

Understanding ERDERA: Europe’s alliance for rare disease research

30 million people in Europe live with a rare disease. Yet most still lack a diagnosis or treatment. So what is ERDERA doing about it?
European Biotech Act 062026

ERDERA Policy Brief: European Biotech Act

The European Rare Diseases Research Alliance (ERDERA), together with the European Reference Networks (ERNs), provides the missing operational layer required to implement the European Biotech Act across the full innovation pathway —from discovery to patient access.
ERDERA News (1)

ERDERA Clinical Trial Call 2026: pre‑announcement and key dates

ERDERA will launch its Clinical Trial Call 2026 (ECTC) on 1 July 2026, supporting multinational, GCP‑compliant early‑phase interventional clinical trials in rare diseases.

ERDERA's

search form